The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma |
| |
Authors: | Kalmadi Sujith R Hussein Mohamad A |
| |
Affiliation: | Cleveland Clinic Foundation, Multiple Myeloma Multidisciplinary Clinical Research Program, Taussig Cancer Center, Cleveland, Ohio 44195, USA. kalmads@ccf.org |
| |
Abstract: | Multiple myeloma is a clonal disorder of plasma cells which is considered incurable with currently available therapies. Substantial advances have been achieved in the past decade with the identification of cellular mechanisms that confer drug resistance. This has resulted in newer agents such as arsenic trioxide (Trisenoxt), lenalidomide (Revlimid) and bortezomib (Velcade) with promising activity in this disease. In this review article we will outline the history, mechanisms of action, pharmacology, and clinical trials of arsenic trioxide in multiple myeloma. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|